BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 31297850)

  • 21. Frequent IDH1/2 mutations in intracranial chondrosarcoma: a possible diagnostic clue for its differentiation from chordoma.
    Arai M; Nobusawa S; Ikota H; Takemura S; Nakazato Y
    Brain Tumor Pathol; 2012 Oct; 29(4):201-6. PubMed ID: 22323113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone.
    van Oosterwijk JG; de Jong D; van Ruler MA; Hogendoorn PC; Dijkstra PD; van Rijswijk CS; Machado I; Llombart-Bosch A; Szuhai K; Bovée JV
    BMC Cancer; 2012 Aug; 12():375. PubMed ID: 22928481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isocitrate dehydrogenase 1 mutations (IDH1) and p16/CDKN2A copy number change in conventional chondrosarcomas.
    Amary MF; Ye H; Forbes G; Damato S; Maggiani F; Pollock R; Tirabosco R; Flanagan AM
    Virchows Arch; 2015 Feb; 466(2):217-22. PubMed ID: 25432631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutation-driven epigenetic alterations as a defining hallmark of central cartilaginous tumours, giant cell tumour of bone and chondroblastoma.
    Venneker S; Szuhai K; Hogendoorn PCW; Bovée JVMG
    Virchows Arch; 2020 Jan; 476(1):135-146. PubMed ID: 31728625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.
    Peterse EFP; Niessen B; Addie RD; de Jong Y; Cleven AHG; Kruisselbrink AB; van den Akker BEWM; Molenaar RJ; Cleton-Jansen AM; Bovée JVMG
    Br J Cancer; 2018 Apr; 118(8):1074-1083. PubMed ID: 29576625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atypical cartilage in type II germ cell tumors of the mediastinum show significantly different patterns of IDH1/2 mutations from conventional chondrosarcoma.
    Warmke LM; Cheng L; Sperling RM; Sen JD; Ulbright TM
    Mod Pathol; 2022 Nov; 35(11):1636-1643. PubMed ID: 35660795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genomic Profiling of Low-grade Intramedullary Cartilage Tumors Can Distinguish Enchondroma From Chondrosarcoma.
    Joseph NM; McGill KC; Horvai AE
    Am J Surg Pathol; 2021 Jun; 45(6):812-819. PubMed ID: 33239505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma.
    Cleven AH; Höcker S; Briaire-de Bruijn I; Szuhai K; Cleton-Jansen AM; Bovée JV
    Am J Surg Pathol; 2015 Nov; 39(11):1576-83. PubMed ID: 26457357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are IDH1 R132 Mutations Associated With Poor Prognosis in Patients With Chondrosarcoma of the Bone?
    Trovarelli G; Sbaraglia M; Angelini A; Bellan E; Pala E; Belluzzi E; Pozzuoli A; Borga C; Dei Tos AP; Ruggieri P
    Clin Orthop Relat Res; 2024 Jan; 482(6):947-56. PubMed ID: 38170705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The H3F3 K36M mutant antibody is a sensitive and specific marker for the diagnosis of chondroblastoma.
    Amary MF; Berisha F; Mozela R; Gibbons R; Guttridge A; O'Donnell P; Baumhoer D; Tirabosco R; Flanagan AM
    Histopathology; 2016 Jul; 69(1):121-7. PubMed ID: 26844533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma.
    Nakagawa M; Nakatani F; Matsunaga H; Seki T; Endo M; Ogawara Y; Machida Y; Katsumoto T; Yamagata K; Hattori A; Fujita S; Aikawa Y; Ishikawa T; Soga T; Kawai A; Chuman H; Yokoyama N; Fukushima S; Yahiro K; Kimura A; Shimada E; Hirose T; Fujiwara T; Setsu N; Matsumoto Y; Iwamoto Y; Nakashima Y; Kitabayashi I
    Oncogene; 2019 Oct; 38(42):6835-6849. PubMed ID: 31406254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CORR Insights®: Are IDH1 R132 Mutations Associated With Poor Prognosis in Patients With Chondrosarcoma of the Bone?
    Ramsey DC
    Clin Orthop Relat Res; 2024 Jun; 482(6):957-959. PubMed ID: 38446419
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinicopathological features of five unusual cases of intraosseous myoepithelial carcinomas, mimicking conventional primary bone tumours, including EWSR1 rearrangement in one case.
    Rekhi B; Joshi S; Panchwagh Y; Gulia A; Borges A; Bajpai J; Jambehekar NA; Pant V; Mandholkar M; Byregowda S; Puri A
    APMIS; 2016 Apr; 124(4):278-90. PubMed ID: 26768122
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutant IDH regulates glycogen metabolism from early cartilage development to malignant chondrosarcoma formation.
    Pathmanapan S; Poon R; De Renshaw TB; Nadesan P; Nakagawa M; Seesankar GA; Ho Loe AK; Zhang HH; Guinovart JJ; Duran J; Newgard CB; Wunder JS; Alman BA
    Cell Rep; 2023 Jun; 42(6):112578. PubMed ID: 37267108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience.
    Setola E; Benini S; Righi A; Gamberi G; Carretta E; Ferrari C; Avnet S; Palmerini E; Magagnoli G; Gambarotti M; Lollini PL; Cesari M; Cocchi S; Paioli A; Longhi A; Scotlandi K; Laginestra MA; Donati DM; Baldini N; Ibrahim T
    BMC Cancer; 2023 Sep; 23(1):907. PubMed ID: 37752419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Possible association of p53 overexpression and mutation with high-grade chondrosarcoma.
    Dobashi Y; Sugimura H; Sato A; Hirabayashi T; Kanda H; Kitagawa T; Kawaguchi N; Imamura T; Machinami R
    Diagn Mol Pathol; 1993 Dec; 2(4):257-63. PubMed ID: 8118603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conventional Chondrosarcoma with Clear Cell Features in the Rib: Report of Two Cases and Review of the Literature.
    Wangsiricharoen S; Jalloh H; James AW; McCarthy EF; Morris CD; Gross JM
    Int J Surg Pathol; 2023 Aug; 31(5):621-626. PubMed ID: 35899291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In Vivo Imaging of Glutamine Metabolism to the Oncometabolite 2-Hydroxyglutarate in IDH1/2 Mutant Tumors.
    Salamanca-Cardona L; Shah H; Poot AJ; Correa FM; Di Gialleonardo V; Lui H; Miloushev VZ; Granlund KL; Tee SS; Cross JR; Thompson CB; Keshari KR
    Cell Metab; 2017 Dec; 26(6):830-841.e3. PubMed ID: 29056515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
    Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
    J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Status of IDH mutations in chondrosarcoma of the jaws.
    You Z; Zhang J; Zhang H; Li X; Sun Z; Sun L
    Int J Oral Maxillofac Surg; 2023 Jan; 52(1):26-31. PubMed ID: 35410781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.